BioXcel Therapeutics, Inc. (BTAI) |
|
31.66 -0.35 (-1.09%)
|
01-27 16:00 |
|
Open: |
32.08 |
Pre. Close: |
32.01 |
|
High:
|
32.48 |
Low:
|
31.535 |
|
Volume:
|
192,911 |
Market Cap:
|
887(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:43:06 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 38.49 One year: 44.95 |
| Support: |
Support1: 24.88  Support2: 19.89 |
| Resistance: |
Resistance1: 32.95 Resistance2: 38.49 |
| Pivot: |
28.39 |
| Moving Average: |
MA(5): 31.7 MA(20): 26.73
MA(100): 16.86 MA(250): 15.77 |
| MACD: |
MACD(12,26): 3.2 Signal(9): 2.9 |
| Stochastic oscillator: |
%K(14,3): 88.3 %D(3): 90.3 |
| RSI: |
RSI(14): 76.2 |
| 52-week: |
High: 32.95 Low: 8.79 |
| Average Vol(K): |
3-Month: 297 (K) 10-Days: 335 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BTAI ] has closed below upper band by 25.6%. Bollinger Bands are 172.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
32.53 - 32.69 |
32.69 - 32.83 |
|
Low:
|
31.16 - 31.33 |
31.33 - 31.47 |
|
Close:
|
31.41 - 31.68 |
31.68 - 31.9 |
|
Company Description |
|
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut. |
Headline News |
Fri, 27 Jan 2023
BTAI: Multiple Catalysts Ahead in 2023 - Yahoo Finance
Thu, 26 Jan 2023
Goldman Sachs Adjusts Price Target on BioXcel Therapeutics to $26 From $16, Maintains Neutral Rating - Marketscreener.com
Wed, 25 Jan 2023
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives Average ... - MarketBeat
Thu, 19 Jan 2023
12 Biotech Stocks Hit New Highs; Did You Make The Most Of It? - Nasdaq
Wed, 11 Jan 2023
BioXcel Therapeutics (BTAI) Reports Promising Top-Line Results ... - StreetInsider.com
Fri, 06 Jan 2023
Biotech Stocks: How Alzheimer's, Genetics And AI Could Drive A ... - Investor's Business Daily
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
28 (M) |
|
% Held by Insiders
|
1.925e+007 (%) |
|
% Held by Institutions
|
32.2 (%) |
|
Shares Short
|
2,360 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.3256e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-96 |
|
Return on Assets (ttm)
|
994.1 |
|
Return on Equity (ttm)
|
-32.9 |
|
Qtrly Rev. Growth
|
137000 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-57.5 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
-4.2 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-117 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.56 |
|
Price to Cash Flow
|
8.94 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
2.18e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
